Neuren Pharmaceuticals Ltd
ASX:NEU

Watchlist Manager
Neuren Pharmaceuticals Ltd Logo
Neuren Pharmaceuticals Ltd
ASX:NEU
Watchlist
Price: 21.64 AUD 4.44% Market Closed
Updated: May 31, 2024
NEU
/
Income Statement
/
Net Income (Common)

Neuren Pharmaceuticals Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Neuren Pharmaceuticals Ltd
Net Income (Common) Peer Comparison

Comparables:
MYX
BOT
PBP
C
CU6
ALA

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Neuren Pharmaceuticals Ltd
ASX:NEU
Net Income (Common)
AU$157.1m
CAGR 3-Years
N/A
CAGR 5-Years
120%
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
Net Income (Common)
AU$117.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Botanix Pharmaceuticals Ltd
ASX:BOT
Net Income (Common)
-AU$14.6m
CAGR 3-Years
-17%
CAGR 5-Years
-3%
CAGR 10-Years
-24%
Probiotec Ltd
ASX:PBP
Net Income (Common)
AU$8.7m
CAGR 3-Years
29%
CAGR 5-Years
-11%
CAGR 10-Years
21%
C
Clarity Pharmaceuticals Ltd
ASX:CU6
Net Income (Common)
-AU$24.6m
CAGR 3-Years
-52%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Arovella Therapeutics Ltd
ASX:ALA
Net Income (Common)
-AU$10.2m
CAGR 3-Years
-1%
CAGR 5-Years
-13%
CAGR 10-Years
N/A

See Also

What is Neuren Pharmaceuticals Ltd's Net Income (Common)?
Net Income (Common)
157.1m AUD

Based on the financial report for Dec 31, 2023, Neuren Pharmaceuticals Ltd's Net Income (Common) amounts to 157.1m AUD.

What is Neuren Pharmaceuticals Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
120%

Over the last year, the Net Income (Common) growth was 85 270%.

ALPHA SPREAD
Join more than 142,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.